US5981719A
(en)
|
1993-03-09 |
1999-11-09 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
US6090925A
(en)
|
1993-03-09 |
2000-07-18 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
US5766629A
(en)
|
1995-08-25 |
1998-06-16 |
Sangstat Medical Corporation |
Oral cyclosporin formulations
|
US6368586B1
(en)
|
1996-01-26 |
2002-04-09 |
Brown University Research Foundation |
Methods and compositions for enhancing the bioadhesive properties of polymers
|
US5985312A
(en)
*
|
1996-01-26 |
1999-11-16 |
Brown University Research Foundation |
Methods and compositions for enhancing the bioadhesive properties of polymers
|
US6120806A
(en)
*
|
1997-06-25 |
2000-09-19 |
Whitmire; David R. |
Oral formulations for controlled release of alcohol deterrents
|
FR2775435B1
(fr)
*
|
1998-02-27 |
2000-05-26 |
Bioalliance Pharma |
Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6905707B2
(en)
*
|
1998-05-28 |
2005-06-14 |
Medical Research Institute |
Controlled release arginine alpha ketoglutarate
|
US20050085498A1
(en)
*
|
1998-05-28 |
2005-04-21 |
Byrd Edward A. |
Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
|
US6197340B1
(en)
*
|
1998-05-28 |
2001-03-06 |
Medical Research Institute |
Controlled release lipoic acid
|
US20040259895A1
(en)
*
|
1998-05-28 |
2004-12-23 |
Medical Research Institute |
Oral formulation of lipid soluble thiamine and lipoic acid
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
US8236352B2
(en)
*
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
CA2346001C
(fr)
*
|
1998-10-01 |
2003-12-30 |
Elan Pharma International, Limited |
Liberation regulee de compositions nanoparticulaires
|
US6984404B1
(en)
|
1998-11-18 |
2006-01-10 |
University Of Florida Research Foundation, Inc. |
Methods for preparing coated drug particles and pharmaceutical formulations thereof
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
NZ552959A
(en)
*
|
1998-11-27 |
2008-06-30 |
Darwin Discovery Ltd |
Compositions and methods for increasing bone mineralization
|
JP3650582B2
(ja)
|
1998-11-30 |
2005-05-18 |
ナノスフェアー インコーポレイテッド |
ポリマー−ナノ粒子ハイブリッド粒子
|
US20040258763A1
(en)
*
|
1999-02-03 |
2004-12-23 |
Bell Steve J.D. |
Methods of manufacture and use of calcium phosphate particles containing allergens
|
AU2753100A
(en)
|
1999-02-03 |
2000-08-25 |
Biosante Pharmaceuticals, Inc. |
Therapeutic calcium phosphate particles and methods of manufacture and use
|
US20020054914A1
(en)
*
|
1999-02-03 |
2002-05-09 |
Tulin Morcol |
Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
|
US6410255B1
(en)
*
|
1999-05-05 |
2002-06-25 |
Aurora Biosciences Corporation |
Optical probes and assays
|
KR100840925B1
(ko)
|
1999-05-14 |
2008-06-24 |
니리어스 파마슈티컬즈, 인크. |
신규한 인터루킨-1 및 종양사멸인자-α의 조절인자들, 상기조절인자들의 합성 및 상기 조절인자들의 사용 방법
|
EP1754488A1
(fr)
|
1999-05-24 |
2007-02-21 |
Introgen Therapeutics, Inc. |
Methodes et compositions de thérapie génique non-virale pour le traitement des maladies hyperprolifératives
|
US6406745B1
(en)
|
1999-06-07 |
2002-06-18 |
Nanosphere, Inc. |
Methods for coating particles and particles produced thereby
|
US20040115134A1
(en)
*
|
1999-06-22 |
2004-06-17 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
RU2155602C1
(ru)
*
|
1999-11-30 |
2000-09-10 |
Оао "Куантум Сатис" |
Инсулинсодержащее лекарственное средство для перорального применения и способ его получения
|
KR100919916B1
(ko)
|
2000-02-23 |
2009-10-07 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
종양 특이적 동물 단백질
|
DE60139544D1
(de)
*
|
2000-02-23 |
2009-09-24 |
Life Technologies Corp |
Veränderte, fluoreszierende proteine
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US6582713B2
(en)
|
2000-04-06 |
2003-06-24 |
Univ. Of Colorado - Colorado Springs |
Compositions and methods for promoting wound healing
|
US10293056B1
(en)
|
2000-05-24 |
2019-05-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
CA2309575A1
(fr)
*
|
2000-05-26 |
2001-11-26 |
James E. Guillet |
Macromolecules a reticulation interne
|
SI1542732T1
(sl)
|
2000-06-20 |
2010-01-29 |
Corixa Corp Csc The United Sta |
Fuzijski proteini Mycobacterium tuberculosis
|
EP1319069B1
(fr)
|
2000-06-28 |
2008-05-21 |
Corixa Corporation |
Compositions et methodes pour le traitement et le diagnostic du cancer du poumon
|
US6602523B1
(en)
|
2000-08-17 |
2003-08-05 |
Technology Holding, Llc. |
Composite material and process for increasing bioavailability and activity of a beneficial agent
|
ES2402045T3
(es)
*
|
2000-11-16 |
2013-04-26 |
The Regents Of The University Of California |
Taxón de actionomiceto marino para el descubrimiento de fármacos y de productos de fermentación
|
AU2002220257A1
(en)
*
|
2000-12-07 |
2002-06-18 |
Board Of Regents, The University Of Texas System |
Methods of treatment involving human mda-7
|
US6977085B2
(en)
*
|
2000-12-22 |
2005-12-20 |
Baxter International Inc. |
Method for preparing submicron suspensions with polymorph control
|
US8067032B2
(en)
*
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
US6884436B2
(en)
*
|
2000-12-22 |
2005-04-26 |
Baxter International Inc. |
Method for preparing submicron particle suspensions
|
US9700866B2
(en)
*
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
US6951656B2
(en)
*
|
2000-12-22 |
2005-10-04 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US20040022862A1
(en)
*
|
2000-12-22 |
2004-02-05 |
Kipp James E. |
Method for preparing small particles
|
US6869617B2
(en)
*
|
2000-12-22 |
2005-03-22 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US20030072807A1
(en)
*
|
2000-12-22 |
2003-04-17 |
Wong Joseph Chung-Tak |
Solid particulate antifungal compositions for pharmaceutical use
|
US7193084B2
(en)
*
|
2000-12-22 |
2007-03-20 |
Baxter International Inc. |
Polymorphic form of itraconazole
|
US20030096013A1
(en)
*
|
2000-12-22 |
2003-05-22 |
Jane Werling |
Preparation of submicron sized particles with polymorph control
|
US20040256749A1
(en)
*
|
2000-12-22 |
2004-12-23 |
Mahesh Chaubal |
Process for production of essentially solvent-free small particles
|
US20050048126A1
(en)
*
|
2000-12-22 |
2005-03-03 |
Barrett Rabinow |
Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
|
EP1515982A4
(fr)
|
2001-05-09 |
2005-10-26 |
Corixa Corp |
Methodes et compositions pour la therapie et le diagnostic du cancer de la prostate
|
US20030185892A1
(en)
*
|
2001-08-17 |
2003-10-02 |
Bell Steve J. D. |
Intraocular delivery compositions and methods
|
US20030095928A1
(en)
*
|
2001-09-19 |
2003-05-22 |
Elan Pharma International Limited |
Nanoparticulate insulin
|
JP2005504090A
(ja)
*
|
2001-09-26 |
2005-02-10 |
バクスター・インターナショナル・インコーポレイテッド |
分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
|
US20060003012A9
(en)
*
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
US7112340B2
(en)
*
|
2001-10-19 |
2006-09-26 |
Baxter International Inc. |
Compositions of and method for preparing stable particles in a frozen aqueous matrix
|
DK1581119T3
(da)
|
2001-12-17 |
2013-05-13 |
Corixa Corp |
Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
|
CA2477780A1
(fr)
*
|
2002-03-05 |
2003-09-18 |
Board Of Regents, The University Of Texas System |
Procedes d'amelioration de l'induction de la reponse immunitaire impliquant mda-7
|
US7799523B2
(en)
|
2002-04-03 |
2010-09-21 |
Celltech R & D, Inc. |
Association of polymorphisms in the SOST gene region with bone mineral density
|
AU2003237798A1
(en)
|
2002-04-05 |
2003-10-27 |
Board Of Regents, The University Of Texas System |
Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions
|
US7176232B2
(en)
*
|
2002-06-24 |
2007-02-13 |
The Regents Of The University Of California |
Salinosporamides and methods for use thereof
|
EP2269618A1
(fr)
|
2002-08-12 |
2011-01-05 |
Jennerex Biotherapeutics ULC |
Virus de vaccinia oncolytique pour usage en combinaison aven une chémiothérapie pour le traitement du cancer
|
WO2004034970A2
(fr)
*
|
2002-09-27 |
2004-04-29 |
Nereus Pharmaceuticals, Inc. |
Lactames macrocycliques
|
US20050051968A1
(en)
*
|
2002-11-13 |
2005-03-10 |
Froesel David William |
Washer toss game
|
CN1849142A
(zh)
|
2002-11-15 |
2006-10-18 |
埃迪尼克斯(开曼)有限公司 |
2′-支链核苷和黄病毒突变
|
AU2003301064A1
(en)
*
|
2002-12-17 |
2004-07-14 |
Massachusetts Institute Of Technology |
Stimuli-responsive systems for controlled drug delivery
|
ZA200505302B
(en)
|
2003-01-06 |
2007-03-28 |
Corixa Corp |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
EP1596872B1
(fr)
*
|
2003-01-24 |
2011-06-22 |
Flora Technology Inc. |
Compositions et procedes pour restaurer la flore bacterienne
|
WO2004078124A2
(fr)
*
|
2003-03-03 |
2004-09-16 |
Board Of Regents, The University Of Texas System |
Procedes et compositions impliquant mda-7
|
ES2586401T3
(es)
|
2003-06-16 |
2016-10-14 |
Ucb Pharma S.A. |
Anticuerpos específicos para la esclerostina y métodos para aumentar la mineralización ósea
|
PL2441767T3
(pl)
*
|
2003-06-20 |
2015-11-30 |
Univ California |
Salinosporamidy i sposoby ich stosowania
|
AU2004253478A1
(en)
*
|
2003-06-20 |
2005-01-13 |
Nereus Pharmaceuticals, Inc. |
Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
|
NZ544637A
(en)
|
2003-07-16 |
2010-04-30 |
Protiva Biotherapeutics Inc |
Lipid encapsulated interfering RNA
|
US7727752B2
(en)
|
2003-07-29 |
2010-06-01 |
Life Technologies Corporation |
Kinase and phosphatase assays
|
EP1525890A1
(fr)
*
|
2003-10-02 |
2005-04-27 |
Complex Biosystems GmbH |
Complexes protéine-protéophore
|
AU2004285468B2
(en)
|
2003-10-22 |
2011-02-24 |
Fred Hutchinson Cancer Research Center |
Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
|
WO2005082396A2
(fr)
*
|
2003-12-01 |
2005-09-09 |
Introgen Therapeutics, Inc. |
Utilisation de mda-7 pour inhiber des organismes infectieux pathogenes
|
JP2007519727A
(ja)
*
|
2004-01-23 |
2007-07-19 |
ネレアス ファーマシューティカルズ インコーポレイテッド |
抗菌薬として有用なビス−インドールピロール
|
CA2555921A1
(fr)
*
|
2004-02-13 |
2005-09-15 |
Nod Pharmaceuticals, Inc. |
Nouveaux procedes et nouvelle composition d'administration de macromolecules par voie orale
|
US20070281041A1
(en)
*
|
2004-03-02 |
2007-12-06 |
Introgen Therapeutics, Inc. |
Compositions and Methods Involving MDA-7 for the Treatment of Cancer
|
MXPA06012421A
(es)
|
2004-04-30 |
2007-01-31 |
Nereus Pharmaceuticals Inc |
Compuestos de heterociclicos y metodos para utilizar los mismos.
|
US7579371B2
(en)
|
2004-04-30 |
2009-08-25 |
Nereus Pharmaceuticals, Inc. |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof
|
CA2837748C
(fr)
|
2004-05-25 |
2016-03-08 |
Oregon Health And Science University |
Vaccination du virus de l'immunodeficience simienne (siv) et du virus de l'immunodeficience humaine (vih) utilisant des vecteurs de vaccin a base de rhcmv et hcmv
|
US20080280973A1
(en)
*
|
2004-06-28 |
2008-11-13 |
Wender Paul A |
Laulimalide Analogues as Therapeutic Agents
|
FR2872703B1
(fr)
*
|
2004-07-07 |
2006-10-06 |
Ethypharm Sa |
Nanoparticules polymeriques composites
|
CN1732962A
(zh)
*
|
2004-08-11 |
2006-02-15 |
张阳德 |
阿霉素-聚氰基丙烯酸正丁脂纳米粒的制备方法
|
CN1733313A
(zh)
*
|
2004-08-11 |
2006-02-15 |
张阳德 |
聚氰基丙烯酸正丁酯纳米颗粒的制备方法
|
US20060078622A1
(en)
*
|
2004-08-13 |
2006-04-13 |
Emisphere Technologies, Inc. |
Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
|
US10583094B2
(en)
|
2004-09-18 |
2020-03-10 |
University Of Maryland |
Therapeutic methods that target the NCCA-ATP channel
|
JP5085326B2
(ja)
|
2004-09-18 |
2012-11-28 |
ユニバーシティ オブ メリーランド,ボルチモア |
NCCa−ATPチャネルを標的とする処置剤およびその使用方法
|
US7282194B2
(en)
*
|
2004-10-05 |
2007-10-16 |
Gp Medical, Inc. |
Nanoparticles for protein drug delivery
|
CA2586035A1
(fr)
*
|
2004-11-01 |
2006-05-11 |
Biosante Pharmaceuticals, Inc. |
Particules therapeutiques de phosphate de calcium destinees a la medecine esthetique ou cosmetique, et procedes de fabrication et d'utilisation
|
DK1830838T3
(da)
*
|
2004-12-03 |
2013-01-21 |
Dana Farber Cancer Inst Inc |
Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme
|
JP2008531481A
(ja)
*
|
2005-02-08 |
2008-08-14 |
ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム |
癌の治療のための、mda−7を含む組成物および方法
|
US7507794B2
(en)
|
2005-02-08 |
2009-03-24 |
Research Development Foundation |
Isolated soluble corticotropin releasing factor receptor type 2 (sCRFR2)
|
ES2259914B1
(es)
*
|
2005-03-14 |
2007-06-16 |
Advanced In Vitro Cell Technologies, S.L. |
Nanoparticulas de quitosano y polietilenglicol como sistema de administracion de moleculas biologicamente activas.
|
CA2602637A1
(fr)
|
2005-03-31 |
2006-10-05 |
Glaxosmithkline Biologicals Sa |
Vaccins destines a lutter contre une infection a chlamydia
|
ITMI20050739A1
(it)
*
|
2005-04-22 |
2006-10-23 |
Effebi Spa |
Piastrina di connsessione valvola-attuatore
|
PT1883665T
(pt)
|
2005-04-22 |
2017-11-14 |
Univ Geneve |
Composições polilactídeo e usos das mesmas
|
DK1877426T3
(da)
|
2005-04-29 |
2012-05-14 |
Glaxosmithkline Biolog Sa |
Fremgangsmåde til forebyggelse eller behandling af M Tuberculosis-infektion.
|
US8003108B2
(en)
*
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
US7592429B2
(en)
*
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
AU2006259594A1
(en)
*
|
2005-06-14 |
2006-12-28 |
Baxter Healthcare S.A. |
Pharmaceutical formulations for minimizing drug-drug interactions
|
US20060280787A1
(en)
*
|
2005-06-14 |
2006-12-14 |
Baxter International Inc. |
Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
|
WO2007015757A2
(fr)
|
2005-07-21 |
2007-02-08 |
Nereus Pharmaceuticals, Inc. |
Modulateurs de facteur de necrose tumorale alpha et d'interleukine-1; syntheses de ces modulateurs et procedes d'utilisation de ceux-ci
|
WO2007016597A2
(fr)
*
|
2005-07-29 |
2007-02-08 |
The Regents Of The University Of California |
Ciblage de secretion de facteur de croissance dependant d'enzyme de conversion de tnf-alpha (tace) dans une therapie anticancereuse
|
KR20080047395A
(ko)
|
2005-08-25 |
2008-05-28 |
다이호야쿠힌고교 가부시키가이샤 |
T세포 인식 에피토프 펩티드를 고정화 또는 내포화한생분해성 나노입자
|
KR20090004839A
(ko)
*
|
2005-09-07 |
2009-01-12 |
제네렉스, 인코포레이티드 |
Gm-csf를 발현하는 폭스바이러스를 사용한 전이성및/또는 전신 파종성 암의 전신 치료법
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
CA2628300C
(fr)
|
2005-11-02 |
2018-04-17 |
Protiva Biotherapeutics, Inc. |
Molecules d'arnsi modifiees et utilisations de celles-ci
|
US20070134341A1
(en)
*
|
2005-11-15 |
2007-06-14 |
Kipp James E |
Compositions of lipoxygenase inhibitors
|
EP1956910B1
(fr)
|
2005-11-23 |
2014-09-17 |
The Board of Regents of The University of Texas System |
Compose cytotoxique speficique du ras oncogene et ses procedes d'utilisation
|
CN102702013B
(zh)
|
2005-11-28 |
2016-02-10 |
Gtx公司 |
核受体结合剂
|
US20090081157A1
(en)
|
2006-01-09 |
2009-03-26 |
Richard Syd Kornbluth |
Immunostimulatory Combinations for Vaccine Adjuvants
|
WO2007092944A2
(fr)
*
|
2006-02-08 |
2007-08-16 |
Introgen Therapeutics, Inc. |
Compositions et procedes impliquant une therapie de gene et une modulation de proteasome
|
EP1876188A1
(fr)
*
|
2006-07-04 |
2008-01-09 |
NanoDel Technologies GmbH |
Polymerisation en miniemulsion en deux étapes
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
US8652782B2
(en)
|
2006-09-12 |
2014-02-18 |
Longhorn Vaccines & Diagnostics, Llc |
Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
|
US9481912B2
(en)
|
2006-09-12 |
2016-11-01 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
|
US8097419B2
(en)
|
2006-09-12 |
2012-01-17 |
Longhorn Vaccines & Diagnostics Llc |
Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
|
US8080645B2
(en)
|
2007-10-01 |
2011-12-20 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection/transport compositions and methods
|
US8481023B2
(en)
|
2006-09-15 |
2013-07-09 |
Ottawa Hospital Research Institute |
Oncolytic rhabdovirus
|
CA2663962A1
(fr)
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Genes regules mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p et voies de signalisation utiles comme cibles dans une intervention therapeutique
|
WO2008070350A2
(fr)
|
2006-10-27 |
2008-06-12 |
The Board Of Regents Of The University Of Texas System |
Procédés et compositions liés aux enveloppements de déshydrons
|
WO2008133722A2
(fr)
*
|
2006-11-10 |
2008-11-06 |
Ucb Pharma S.A. |
Anticorps et diagnostics
|
EP2423226A3
(fr)
|
2006-11-10 |
2012-05-30 |
Amgen Inc. |
Diagnostic à base d'anticorps et thérapeutique
|
WO2008140587A2
(fr)
|
2006-11-21 |
2008-11-20 |
The Regents Of The University Of California |
Rhamm, co-récepteur et interactions avec d'autres récepteurs dans la motilité des cellules cancéreuses et identification de populations cellulaires de progéniteurs cancéreux
|
US20080138418A1
(en)
*
|
2006-12-07 |
2008-06-12 |
Tong Shen Enterprise Co., Ltd. |
Nanoparticles composed of alkyl-cyanoacrylate polymers
|
EP3103451A1
(fr)
|
2007-01-12 |
2016-12-14 |
University of Maryland, Baltimore |
Ciblage de canal ncca-atp destiné à protéger les organes après un épisode ischémique
|
US8679539B2
(en)
*
|
2007-01-31 |
2014-03-25 |
Tong Shen Enterprise Co., Ltd. |
Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process for the preparation thereof
|
WO2008095195A2
(fr)
*
|
2007-02-02 |
2008-08-07 |
Nereus Pharmaceuticals, Inc. |
Formulations lyophilisées de salinosporamide a
|
CN101674730B
(zh)
|
2007-02-02 |
2014-09-10 |
贝勒医学院 |
用于治疗代谢疾病的组合物和方法
|
CA2618099C
(fr)
|
2007-02-09 |
2016-09-20 |
University Of Maryland, Baltimore |
Antagonistes d'un canal cationique non selectif dans des cellules neuronales
|
KR20080084528A
(ko)
|
2007-03-15 |
2008-09-19 |
제네렉스 바이오테라퓨틱스 인크. |
종양살상형 백시니아 바이러스 암 치료
|
MX351247B
(es)
*
|
2007-04-04 |
2017-10-05 |
Infectious Disease Res Institute Star |
Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
EP3492596A1
(fr)
|
2007-04-09 |
2019-06-05 |
University of Florida Research Foundation, Inc. |
Compositions de vecteur raav comprenant des protéines de capside à tyrosine modifié et procédés d'utilisation
|
US8426467B2
(en)
|
2007-05-22 |
2013-04-23 |
Baxter International Inc. |
Colored esmolol concentrate
|
US8722736B2
(en)
|
2007-05-22 |
2014-05-13 |
Baxter International Inc. |
Multi-dose concentrate esmolol with benzyl alcohol
|
MX2009013354A
(es)
|
2007-06-04 |
2010-07-06 |
Univ Ben Gurion |
Compuestos de triarilo y composiciones que los contienen.
|
CA2691199C
(fr)
|
2007-06-22 |
2017-09-12 |
Marc J. Simard |
Inhibiteurs de canaux nc<sb>ca-atp</sb> pour therapie
|
US20090017167A1
(en)
*
|
2007-07-11 |
2009-01-15 |
Herbalife International Inc. |
Mixture and beverage made therefrom for protecting cellular hydration
|
US11041215B2
(en)
|
2007-08-24 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
PCR ready compositions and methods for detecting and identifying nucleic acid sequences
|
US9683256B2
(en)
|
2007-10-01 |
2017-06-20 |
Longhorn Vaccines And Diagnostics, Llc |
Biological specimen collection and transport system
|
EP2772267B1
(fr)
|
2007-08-27 |
2016-04-27 |
Longhorn Vaccines and Diagnostics, LLC |
Compositions immunogènes et procédés
|
US10004799B2
(en)
|
2007-08-27 |
2018-06-26 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
DK2535428T3
(en)
|
2007-10-01 |
2015-11-23 |
Longhorn Vaccines & Diagnostics Llc |
Biological prøvesamlings- and transport system, and methods of using
|
US11041216B2
(en)
|
2007-10-01 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
|
US8394816B2
(en)
*
|
2007-12-07 |
2013-03-12 |
Irene Ghobrial |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
|
US20110044978A1
(en)
*
|
2007-12-14 |
2011-02-24 |
Amgen Inc. |
Method for treating bone fracture
|
JP5618284B2
(ja)
|
2007-12-27 |
2014-11-05 |
昇一 城武 |
グラム陽性細菌用抗菌剤
|
WO2009082817A1
(fr)
|
2007-12-27 |
2009-07-09 |
Protiva Biotherapeutics, Inc. |
Silençage de l'expression de la polo-like kinase à l'aide d'un arn interférent
|
EP2281041B1
(fr)
|
2008-04-15 |
2014-07-02 |
Protiva Biotherapeutics Inc. |
Réduction au silence de l'expression du gène csn5 au moyen d'arn interférant
|
PL2279254T3
(pl)
|
2008-04-15 |
2017-11-30 |
Protiva Biotherapeutics Inc. |
Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
|
US8258111B2
(en)
|
2008-05-08 |
2012-09-04 |
The Johns Hopkins University |
Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
|
BRPI0908686B8
(pt)
*
|
2008-05-09 |
2021-05-25 |
South Dakota State Univ |
método de produção de nanopartículas não-imunogênicas, nanopartícula não-imunogênica terapeuticamente ativa, composição terapêutica, uso de uma nanopartícula não-imunogênica e kit para a produção de nanopartículas não-imunogênicas
|
KR20110011645A
(ko)
*
|
2008-05-12 |
2011-02-08 |
니리어스 파마슈티컬즈, 인코퍼레이션 |
프로테아좀 저해제로서의 살리노스포라마이드 유도체
|
US8404471B2
(en)
|
2008-06-26 |
2013-03-26 |
Atyr Pharma, Inc. |
Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities
|
EP2719380A3
(fr)
|
2008-09-16 |
2014-07-30 |
University of Maryland, Baltimore |
Inhibiteurs de SUR1 pour la thérapie
|
US8349899B1
(en)
|
2008-12-03 |
2013-01-08 |
Arrowhead Center, Inc. |
Selective inhibitors of EG5 motors and methods of use
|
US8765817B1
(en)
|
2008-12-03 |
2014-07-01 |
Arrowhead Center, Inc. |
Selective inhibitors of EG5 motors and methods of use
|
WO2010099477A2
(fr)
|
2009-02-27 |
2010-09-02 |
Atyr Pharma, Inc. |
Motifs structuraux de polypeptides associés à une activité de signalisation cellulaire
|
ES2742251T3
(es)
|
2009-03-16 |
2020-02-13 |
Pangu Biopharma Ltd |
Composiciones y procedimientos que comprenden variantes de splicing de histidil-tarn sintetasa que tienen actividades biológicas no canónicas
|
CA2757289A1
(fr)
|
2009-03-31 |
2010-10-21 |
Atyr Pharma, Inc. |
Compositions et procedes impliquant des aspartyl-arnt synthetases presentant des activites biologiques non canoniques
|
ES2702049T3
(es)
|
2009-04-24 |
2019-02-27 |
Univ Vanderbilt |
Inducción anti-TGF-beta de crecimiento óseo
|
WO2010135714A2
(fr)
|
2009-05-22 |
2010-11-25 |
The Methodist Hospital Research Institute |
Méthodes de modulation de l'expression des adipocytes utilisant des compositions de micro-arn
|
WO2010138263A2
(fr)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Nouveaux virus adéno-associés (aav) et leurs utilisations
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
WO2011011781A1
(fr)
|
2009-07-24 |
2011-01-27 |
Baylor College Of Medicine |
Procédés de modulation d'acides à chaînes ramifiées et leurs utilisations
|
CA2771769C
(fr)
|
2009-08-28 |
2019-10-29 |
Research Development Foundation |
Analogues d'urocortine 2 et leurs utilisations
|
DK2477499T3
(en)
|
2009-09-14 |
2018-06-06 |
Sillajen Biotherapeutics Inc |
COMBINATION CANCER THERAPY WITH ONCOLYTIC VACCINIA VIRUS
|
CA2775092A1
(fr)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions et procedes pour reduire au silence des genes exprimes dans le cancer
|
AU2010329551B2
(en)
|
2009-12-10 |
2016-02-11 |
Turnstone Limited Partnership |
Oncolytic rhabdovirus
|
US9127268B2
(en)
|
2009-12-11 |
2015-09-08 |
Atyr Pharma, Inc. |
Aminoacyl tRNA synthetases for modulating inflammation
|
WO2011072266A2
(fr)
|
2009-12-11 |
2011-06-16 |
Atyr Pharma, Inc. |
Aminoacyl-arnt synthétases destinées à moduler l'hématopoïèse
|
TW201132353A
(en)
|
2009-12-18 |
2011-10-01 |
Amgen Inc |
WISE binding agents and epitopes
|
HUE031184T2
(en)
|
2010-01-27 |
2017-06-28 |
Glaxosmithkline Biologicals Sa |
Modified tuberculosis antigens
|
EP2826860B1
(fr)
|
2010-04-23 |
2018-08-22 |
University of Massachusetts |
Vecteurs AAV de ciblage du système nerveux central et leurs procédés d'utilisation
|
ES2689520T3
(es)
|
2010-04-23 |
2018-11-14 |
Kempharm, Inc. |
Formulación terapéutica para reducir los efectos secundarios de fármacos
|
EP3444346B1
(fr)
|
2010-04-23 |
2022-07-27 |
University of Massachusetts |
Traitement de troubles liés au cholestérol basé sur aav
|
EP2561067B1
(fr)
|
2010-04-23 |
2018-11-14 |
University of Florida Research Foundation, Inc. |
Compositions de guanylate cyclase raav et méthodes de traitement de l'amaurose-1 congénitale de leber (lca1)
|
AU2011248625B2
(en)
|
2010-04-26 |
2017-01-05 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
|
JP6294074B2
(ja)
|
2010-04-27 |
2018-03-14 |
エータイアー ファーマ, インコーポレイテッド |
イソロイシルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
EP2563911B1
(fr)
|
2010-04-28 |
2021-07-21 |
aTyr Pharma, Inc. |
Compositions thérapeutiques, diagnostiques et d'anticorps à base de fragments de protéines d'aminoacyl-arnt synthétases
|
WO2011139907A2
(fr)
|
2010-04-29 |
2011-11-10 |
Atyr Pharma, Inc. |
Découverte innovatrice de compositions thérapeutiques, diagnostiques, et d'anticorps associées aux fragments protéiques des valyle arnt synthésases
|
WO2011139854A2
(fr)
|
2010-04-29 |
2011-11-10 |
Atyr Pharma, Inc. |
Découverte innovante de compositions thérapeutiques, diagnostiques et à based'anticorps associées à des fragments protéiques d'asparaginyl-arnt-synthétases
|
WO2011140135A2
(fr)
|
2010-05-03 |
2011-11-10 |
Atyr Pharma, Inc. |
Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées des fragments protéiques de méthionyl-arnt-synthétases
|
ES2623805T3
(es)
|
2010-05-03 |
2017-07-12 |
Atyr Pharma, Inc. |
Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de fenilalanil-alfa-ARNt sintetasas
|
WO2011139986A2
(fr)
|
2010-05-03 |
2011-11-10 |
Atyr Pharma, Inc. |
Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps liées à des fragments protéiques d'arginyle-arnt synthétases
|
EP2566499B1
(fr)
|
2010-05-04 |
2017-01-25 |
aTyr Pharma, Inc. |
Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées à des fragments protéiques de complexe multi-arnt synthétase p38
|
WO2011141704A1
(fr)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Nouveaux lipides cationiques cycliques et procédés d'utilisation
|
EP2569276B1
(fr)
|
2010-05-12 |
2021-02-24 |
Arbutus Biopharma Corporation |
Nouveaux lipides cationiques et procédés d'utilisation de ceux-ci
|
US8945541B2
(en)
|
2010-05-14 |
2015-02-03 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
|
EA037392B1
(ru)
|
2010-05-14 |
2021-03-23 |
Эмджен Инк. |
Композиции с высокой концентрацией антител
|
CN103096914B
(zh)
|
2010-05-17 |
2015-08-12 |
Atyr医药公司 |
与亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
JP6046607B2
(ja)
|
2010-05-27 |
2016-12-21 |
エータイアー ファーマ, インコーポレイテッド |
グルタミニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
JP5906237B2
(ja)
|
2010-06-01 |
2016-04-20 |
エータイアー ファーマ, インコーポレイテッド |
リジルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
CA2804416C
(fr)
|
2010-07-12 |
2020-04-28 |
Atyr Pharma, Inc. |
Decouverte innovante de compositions therapeutiques, de diagnostic et d'anticorps se rapportant a des fragments proteiques de glycyl-arnt synthetases
|
US10865445B2
(en)
|
2010-08-18 |
2020-12-15 |
Fred Hutchinson Cancer Research Center |
Methods for alleviating facioscapulohumeral dystrophy (FSHD) by N siRNA molecule inhibiting the expression of DUX4-FL
|
CN103108650A
(zh)
|
2010-08-25 |
2013-05-15 |
Atyr医药公司 |
与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
WO2012057904A1
(fr)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Antigènes du mycobacterium tuberculosis et leurs combinaisons présentant une séroréactivité élevée
|
US20120114688A1
(en)
|
2010-11-08 |
2012-05-10 |
Infectious Disease Research Institute |
Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
|
JP6121910B2
(ja)
|
2011-01-04 |
2017-04-26 |
シラジェン バイオセラピューティクス インコーポレイテッド |
腫瘍溶解性ワクシニアウイルスの投与による腫瘍抗原に対する抗体の生成および腫瘍特異的補体依存性細胞傷害の生成
|
US9403885B2
(en)
|
2011-01-11 |
2016-08-02 |
Fate Therapeutics, Inc. |
Wnt compositions and therapeutic uses of such compositions
|
WO2012103328A1
(fr)
|
2011-01-26 |
2012-08-02 |
The Methodist Hospital Research Institute |
Antagonistes polyvalents non peptidiques marqués de l'intégrine alpha-ν bêta-3, compositions les renfermant et leur utilisation
|
CN103476931A
(zh)
|
2011-02-03 |
2013-12-25 |
米尔纳医疗股份有限公司 |
Mir-34的合成模拟物
|
JP2014506789A
(ja)
|
2011-02-03 |
2014-03-20 |
マーナ セラピューティクス インコーポレイテッド |
miR−124の合成模倣体
|
US8986739B2
(en)
|
2011-02-28 |
2015-03-24 |
Nicholas V. Perricone |
Treatment of urinary incontinence using nitrone spin traps
|
MX2013010011A
(es)
|
2011-03-01 |
2014-10-24 |
Amgen Inc |
Agentes de unión biespecífica.
|
AU2012236962B2
(en)
|
2011-03-25 |
2017-05-11 |
Amgen Inc. |
Anti-sclerostin antibody crystals and formulations thereof
|
EP2692742A4
(fr)
|
2011-03-31 |
2014-10-01 |
Nanocame Co Ltd |
Nouvelle technique de préparation d'une structure d'ordre supérieur présentant un effet anti-cellulaire
|
RS57877B1
(sr)
|
2011-04-19 |
2018-12-31 |
Amgen Inc |
Metoda za lečenje osteoporoze
|
EP2718427B1
(fr)
|
2011-06-08 |
2017-01-11 |
Children's Hospital of Eastern Ontario Research Institute Inc. |
Compositions pour le traitement du glioblastome
|
US8858928B2
(en)
|
2011-06-10 |
2014-10-14 |
Bluebird Bio, Inc. |
Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
|
CA2837651A1
(fr)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions et methodes pour la therapie et le diagnostic du cancer
|
AU2012287120B2
(en)
|
2011-07-22 |
2017-02-23 |
The University Of Chicago |
Treatments for migraine and related disorders
|
PT2739311T
(pt)
|
2011-08-04 |
2018-03-26 |
Amgen Inc |
Método para tratamento de defeitos de lacunas ósseas
|
US9655905B2
(en)
|
2011-09-14 |
2017-05-23 |
King Abdullah University Of Science And Technology |
Treatment of sickle cell disease
|
WO2013041969A2
(fr)
|
2011-09-21 |
2013-03-28 |
King Abdullah University Of Science And Technology |
Famille de gènes de biosynthèse de la didemnine chez tistrella mobilis
|
CA2849720C
(fr)
|
2011-09-23 |
2019-06-25 |
Bluebird Bio, Inc. |
Procedes de therapie genique ameliores
|
WO2013095736A2
(fr)
|
2011-09-27 |
2013-06-27 |
The Methodist Hospital Research Institute |
Nanoassemblage d'or-en-silicium pour une thérapie thermique et procédés d'utilisation
|
EP4095236A1
(fr)
|
2011-09-30 |
2022-11-30 |
Bluebird Bio, Inc. |
Composés permettant d'améliorer la transduction virale
|
EP2768481A4
(fr)
|
2011-10-21 |
2015-07-08 |
Subhash Desai |
Compositions pour la réduction d'effets secondaires
|
EP3815685A3
(fr)
|
2011-10-31 |
2021-10-13 |
The Methodist Hospital Research Institute |
Composé comprenant un fragment de ciblage/recherche de mao pour le traitement de gliomes humains
|
EP2776451B1
(fr)
|
2011-11-11 |
2018-07-18 |
Fred Hutchinson Cancer Research Center |
Immunothérapie par des lymphocytes t ciblant la cycline a1 pour le traitement du cancer
|
EP3750544A3
(fr)
|
2011-11-30 |
2021-03-24 |
Emory University |
Inhibiteurs jak destinées à la prévention ou au traitement des infections virales
|
US9546367B2
(en)
|
2011-12-07 |
2017-01-17 |
Jenny Chee Ning Chang |
siRNA compositions and methods for inhibiting gene expression in tumor initiating cells of breast cancer
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
SG10201509629QA
(en)
|
2011-12-28 |
2015-12-30 |
Amgen Inc |
Method Of Treating Alveolar Bone Loss Through The Use Of Anti-Sclerostin Antibodies
|
EP2805617A4
(fr)
*
|
2012-01-19 |
2015-08-12 |
Shoichi Shirotake |
Agent antibactérien dirigé contre des bactéries provoquant une maladie des plantes
|
CA3207612A1
(fr)
|
2012-01-26 |
2013-08-01 |
Longhorn Vaccines And Diagnostics, Llc |
Sequences et vaccins antigeniques composites
|
WO2013123282A1
(fr)
|
2012-02-16 |
2013-08-22 |
The University Of Toledo |
Vaccins anticancéreux présentant un xéno-antigène et leur procédé de fabrication
|
WO2013126803A1
(fr)
|
2012-02-24 |
2013-08-29 |
Protiva Biotherapeutics Inc. |
Lipides cationiques trialkylés et leurs procédés d'utilisation
|
AR092821A1
(es)
|
2012-04-20 |
2015-05-06 |
Sucampo Ag |
Conjugado de derivado de acido graso-polimero
|
US20150342897A1
(en)
*
|
2012-05-16 |
2015-12-03 |
Glaxo Group Limited |
Polypeptide loaded poca nanoparticles for oral administration
|
CN104428005B
(zh)
|
2012-05-23 |
2019-05-10 |
俄亥俄州立大学 |
用于反义寡核苷酸递送的脂质纳米颗粒组合物
|
EP3626267A1
(fr)
|
2012-07-05 |
2020-03-25 |
UCB Pharma, S.A. |
Traitement pour maladies osseuses
|
ES2969734T3
(es)
|
2012-08-03 |
2024-05-22 |
Access To Advanced Health Inst |
Composiciones y métodos para tratar una infección activa por Mycobacterium tuberculosis
|
US20150258198A1
(en)
*
|
2012-08-14 |
2015-09-17 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
US20150224176A1
(en)
*
|
2012-08-14 |
2015-08-13 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
JP2016508504A
(ja)
|
2013-02-01 |
2016-03-22 |
サンタ マリア バイオセラピューティクス インコーポレイテッド |
対象に対する抗アクチビン−a化合物の投与
|
ES2741147T3
(es)
|
2013-02-21 |
2020-02-10 |
Turnstone Lp |
Composición de vacuna
|
US10208012B2
(en)
|
2013-03-13 |
2019-02-19 |
Board Of Regents, The University Of Texas System |
Compounds for treating inflammatory and hyperproliferative diseases
|
BR112015024860B1
(pt)
|
2013-03-28 |
2023-11-07 |
Access To Advanced Health Institute |
Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
|
US10006049B2
(en)
|
2013-05-16 |
2018-06-26 |
University Of Florida Research Foundation, Incorporated |
Hairpin mRNA elements and methods for the regulation of protein translation
|
WO2015011633A1
(fr)
|
2013-07-23 |
2015-01-29 |
Protiva Biotherapeutics, Inc. |
Compositions et procédés pour l'administration d'arn messager
|
AU2014347668A1
(en)
|
2013-11-05 |
2016-05-19 |
Ben-Gurion University Of The Negev Research And Development Authority |
Compounds for the treatment of diabetes and disease complications arising from same
|
US10328127B2
(en)
|
2013-12-02 |
2019-06-25 |
Baylor College Of Medicine |
Methods for stimulation of appetite and increase in weight by administration of asprosin
|
JP6533213B2
(ja)
|
2014-02-27 |
2019-06-19 |
昇一 城武 |
抗ウイルス剤
|
CN111620830A
(zh)
|
2014-03-14 |
2020-09-04 |
北卡罗来纳大学教堂山分校 |
用于抑制雄性生育力的小分子
|
KR20160143775A
(ko)
|
2014-04-08 |
2016-12-14 |
더 메서디스트 하스피틀 |
iNOS-억제 조성물들 및 이들의 유방암 치료제로서의 용도
|
US9693994B2
(en)
|
2014-04-09 |
2017-07-04 |
Research Development Foundation |
Class IIa HDAC inhibitors for the treatment of infection
|
WO2015164786A1
(fr)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Vecteurs de virus adéno-associés recombinants utiles pour réduire une immunité contre des produits transgéniques
|
WO2015196142A1
(fr)
|
2014-06-20 |
2015-12-23 |
Aveo Pharmaceuticals, Inc. |
Traitement de l'insuffisance cardiaque congestive et d'autres dysfonctionnements cardiaques à l'aide d'un modulateur gdf15
|
US20170137506A1
(en)
|
2014-06-20 |
2017-05-18 |
Aveo Pharmaceuticals, Inc. |
Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
|
US10278986B2
(en)
|
2014-08-14 |
2019-05-07 |
The Regents Of The University Of Colorado, A Body Corporate |
Antibody-siRNA conjugates and uses therefor
|
TWI691597B
(zh)
|
2014-09-01 |
2020-04-21 |
中央研究院 |
延長壽命與抑制腫瘤發生的動物模型
|
MX2017002750A
(es)
|
2014-09-02 |
2017-08-02 |
Singh Bhupinder |
Metodo para marcar una molecula deuterada o no deuterada y formulaciones farmaceuticas para tratamiento.
|
EP3189143B1
(fr)
|
2014-09-04 |
2019-08-07 |
Memorial Sloan-Kettering Cancer Center |
Thérapie génique globale destinée à traiter les hémoglobinopathies
|
WO2016049470A1
(fr)
|
2014-09-25 |
2016-03-31 |
Aveo Pharmaceuticals, Inc. |
Procédés d'inversion de la cachexie et de prolongation de la survie, comprenant l'administration d'un modulateur de gdf15 et d'un agent anticancéreux
|
EP3201338B1
(fr)
|
2014-10-02 |
2021-11-03 |
Arbutus Biopharma Corporation |
Compositions et méthodes d'extinction de l'expression du gène du virus de l'hépatite b
|
US10711270B2
(en)
|
2014-10-03 |
2020-07-14 |
University Of Massachusetts |
High efficiency library-identified AAV vectors
|
IL251588B1
(en)
|
2014-10-08 |
2024-05-01 |
Pacific Northwest Res Institute |
Methods and preparations for increasing the potency of antifungal agents
|
RU2020140209A
(ru)
|
2014-10-21 |
2021-01-25 |
Юниверсити Оф Массачусетс |
Варианты рекомбинантных aav и их применения
|
WO2016073184A1
(fr)
|
2014-11-04 |
2016-05-12 |
Dana Farber Cancer Institute, Inc. |
Compositions et procédés pour le traitement d'un myélome multiple
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
EP3233131A1
(fr)
|
2014-12-16 |
2017-10-25 |
Board of Regents of the University of Nebraska |
Thérapie génique pour la maladie de steinert juvénile
|
CN107635575A
(zh)
|
2015-03-10 |
2018-01-26 |
纽约市哥伦比亚大学理事会 |
重组glut1腺相关病毒载体构建体以及用于恢复glut1表达的相关方法
|
US11285190B2
(en)
|
2015-04-20 |
2022-03-29 |
The Board Of Regents Of The University Of Texas System |
CLEC11a is a bone growth agent
|
WO2016172155A1
(fr)
|
2015-04-23 |
2016-10-27 |
University Of Massachusetts |
Modulation de l'expression d'un transgène du vecteur aav
|
WO2016183292A1
(fr)
|
2015-05-14 |
2016-11-17 |
Longhorn Vaccines And Diagnostics, Llc |
Procédés rapides pour l'extraction d'acides nucléiques provenant d'échantillons biologiques
|
WO2016197132A1
(fr)
|
2015-06-04 |
2016-12-08 |
Protiva Biotherapeutics Inc. |
Traitement d'une infection à virus de l'hépatite b à de l'aide de crispr
|
WO2016205615A1
(fr)
|
2015-06-17 |
2016-12-22 |
The Johns Hopkins University |
Tdp-43 dans une maladie dégénérative
|
EP3329003A2
(fr)
|
2015-07-29 |
2018-06-06 |
Arbutus Biopharma Corporation |
Compositions et méthodes de silençage de l'expression du gène du virus de l'hépatite b
|
US20170056485A1
(en)
|
2015-08-31 |
2017-03-02 |
Sciotec Diagnostic Technologies Gmbh |
Crystallized xylose isomerase in prevention of the development of non-alcoholic fatty liver disease
|
CA3002982A1
(fr)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Procedes et compositions pour le traitement du desequilibre metabolique dans une maladie neurodegenerative
|
EP3371221A2
(fr)
|
2015-11-07 |
2018-09-12 |
MultiVir Inc. |
Méthodes et compositions comprenant une thérapie génique suppressive de tumeur et le blocage du point de contrôle immunitaire pour le traitement du cancer
|
CN108884448B
(zh)
|
2016-01-27 |
2022-12-30 |
昂克诺斯公司 |
溶瘤病毒载体及其用途
|
WO2017132321A1
(fr)
|
2016-01-29 |
2017-08-03 |
The Johns Hopkins University |
Nouveaux inhibiteurs de la croissance bactérienne
|
US11060088B2
(en)
|
2016-02-12 |
2021-07-13 |
University Of Massachusetts |
Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
|
WO2017143112A2
(fr)
|
2016-02-17 |
2017-08-24 |
The Johns Hopkins University |
Oxazolidinone pour le traitement d'infections par un bacille de la tuberculose
|
US11149060B2
(en)
|
2016-02-19 |
2021-10-19 |
University Of Delaware |
Functionalized nanoparticles for enhanced affinity precipitation of proteins
|
EP3419602A1
(fr)
|
2016-02-22 |
2019-01-02 |
The Methodist Hospital |
Compositions de vésicules protéo-lipidiques biomimétiques et leurs utilisations
|
WO2017147370A1
(fr)
|
2016-02-24 |
2017-08-31 |
The Johns Hopkins University |
Nouvelles protéines antivirales et leur utilisations dans des méthodes thérapeutiques
|
KR20180114946A
(ko)
|
2016-03-02 |
2018-10-19 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
면역요법을 위한 sting 활성화 나노백신
|
DK3423110T3
(da)
|
2016-03-03 |
2021-11-15 |
Univ Massachusetts |
Lineært duplex-dna med lukket ende til ikke-viral genoverførsel
|
WO2017155935A1
(fr)
|
2016-03-07 |
2017-09-14 |
The Johns Hopkins University |
Agents pharmaceutiques ciblant des cellules souches cancéreuses
|
US11965009B2
(en)
|
2016-03-10 |
2024-04-23 |
The Johns Hopkins University |
Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
|
BR112018068055A2
(pt)
|
2016-03-10 |
2019-01-08 |
Univ Johns Hopkins |
métodos para produção de proteínas de fusão de toxina da difteria monoméricas livre de agregados e usos terapêuticas
|
US11203626B2
(en)
|
2016-03-10 |
2021-12-21 |
The Johns Hopkins University |
Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
JP2019510088A
(ja)
|
2016-03-17 |
2019-04-11 |
ザ ジョンズ ホプキンス ユニバーシティーThe Johns Hopkins University |
Parisのファルネシル化によってパーキンソン病を予防または治療する方法
|
EP3436609B1
(fr)
|
2016-03-30 |
2022-05-04 |
The Johns Hopkins University |
Spécificité du olfr90 et procédés de détection
|
WO2017189483A1
(fr)
|
2016-04-25 |
2017-11-02 |
The Johns Hopkins University |
Dosages du znt8 pour le développement de médicaments et compositions pharmaceutiques
|
JP2019521095A
(ja)
|
2016-05-21 |
2019-07-25 |
インフェクシャス ディズィーズ リサーチ インスティチュート |
二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
|
EP3478838A1
(fr)
|
2016-06-30 |
2019-05-08 |
Arbutus Biopharma Corporation |
Compositions et procédés pour l'administration d'arn messager
|
JP7493334B2
(ja)
|
2016-07-05 |
2024-05-31 |
ユニバーシティ オブ マサチューセッツ |
緑内障における神経保護療法としてのsFasLのAAV2媒介遺伝子送達
|
KR102619496B1
(ko)
|
2016-07-19 |
2023-12-29 |
유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
Stat3를 타겟으로 하는 종양용해성 바이러스
|
US9963498B2
(en)
|
2016-08-18 |
2018-05-08 |
Wisconsin Alumni Research Foundation |
Peptides that inhibit syndecan-1 activation of VLA-4 and IGF-1R
|
WO2018053294A1
(fr)
|
2016-09-16 |
2018-03-22 |
Infectious Disease Research Institute |
Vaccins comprenant des polypeptides de mycobacterium leprae pour la prévention, le traitement et le diagnostic de la lèpre
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
US11149275B2
(en)
|
2016-10-10 |
2021-10-19 |
The Johns Hopkins University |
Device and method to treat esophageal disorders
|
US11491114B2
(en)
|
2016-10-12 |
2022-11-08 |
Curioralrx, Llc |
Formulations for enteric delivery of therapeutic agents
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
JP2020510624A
(ja)
|
2016-12-12 |
2020-04-09 |
マルチビア インコーポレイテッド |
がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
|
US10434089B2
(en)
|
2017-01-25 |
2019-10-08 |
The Johns Hopkins University |
Avibactam and carbapenems antibacterial agents
|
EP4309739A3
(fr)
|
2017-01-27 |
2024-04-17 |
The Methodist Hospital |
Plate-forme de structure c ur/écorce pour immunothérapie
|
WO2018146689A1
(fr)
|
2017-02-12 |
2018-08-16 |
Ben-Gurion University Of The Negev Research And Development Authority |
Composés activant la télomérase destinés à être utilisés dans la fertilité et applications associées
|
US20210139932A1
(en)
|
2017-05-03 |
2021-05-13 |
Biomarin Pharmaceutical Inc. |
Improved lentiviruses for transduction of hematopoietic stem cells
|
EP3635122A4
(fr)
|
2017-06-06 |
2021-03-31 |
University of Massachusetts |
Vecteurs aav à autorégulation pour l'expression sans risque de mecp2 dans le syndrome de rett
|
WO2019014044A1
(fr)
|
2017-07-12 |
2019-01-17 |
The Johns Hopkins University |
Auto-antigène znt8 à base de protéoliposomes pour le diagnostic du diabète de type 1
|
EP3658165A4
(fr)
|
2017-07-26 |
2021-09-01 |
Oncorus, Inc. |
Vecteurs viraux oncolytiques et leurs utilisations
|
WO2019028469A1
(fr)
|
2017-08-04 |
2019-02-07 |
The Methodist Hospital |
Compositions mitochondriales a polymère fonctionnalisé et procédés d'utilisation dans une transplantation cellulaire et pour modifier un phénotype métabolique
|
JP7339942B2
(ja)
|
2017-09-08 |
2023-09-06 |
アクセス ツー アドバンスト ヘルス インスティチュート |
サポニンを含むリポソーム製剤および使用方法
|
US20200330541A1
(en)
|
2017-11-16 |
2020-10-22 |
University Of Maine System Board Of Trustees |
Compositions and methods for modulating endothelial cell migration and angiogenesis
|
AU2018378683A1
(en)
|
2017-12-06 |
2020-07-02 |
Memorial Sloan-Kettering Cancer Center |
Globin gene therapy for treating hemoglobinopathies
|
WO2019118527A1
(fr)
|
2017-12-14 |
2019-06-20 |
The Johns Hopkins University |
Nouveaux inhibiteurs antifongiques
|
TW201936201A
(zh)
|
2017-12-14 |
2019-09-16 |
美商堅固生物科技公司 |
基因之非病毒生產及遞送
|
BR112020013715A2
(pt)
|
2018-01-05 |
2020-12-01 |
Ottawa Hospital Research Institute |
vetores de vaccinia modificados
|
WO2020036635A2
(fr)
|
2018-03-19 |
2020-02-20 |
Multivir Inc. |
Procédés et compositions comprenant une thérapie génique suppressive de tumeur et des agonistes de cd122/cd132 pour le traitement du cancer
|
KR20200135433A
(ko)
|
2018-03-23 |
2020-12-02 |
유니버시티 오브 매사추세츠 |
골 장애 치료를 위한 유전자 치료제
|
WO2019191119A1
(fr)
|
2018-03-28 |
2019-10-03 |
Herbalife International Of America, Inc. |
Acétylation de polysaccharides
|
EP3774879A1
(fr)
|
2018-03-30 |
2021-02-17 |
Amgen Inc. |
Variants d'anticorps anti-c-terminal
|
EP3784290A4
(fr)
|
2018-04-27 |
2022-03-23 |
University of Massachusetts |
Capsides de vaa identifiés par la sélection d'une bibliothèque in vivo
|
AU2019265663B2
(en)
|
2018-05-08 |
2024-06-13 |
Rutgers, The State University Of New Jersey |
AAV-compatible laminin-linker polymerization proteins
|
KR102167755B1
(ko)
|
2018-05-23 |
2020-10-19 |
주식회사 큐어바이오 |
단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
|
AU2019347666A1
(en)
|
2018-09-28 |
2021-03-25 |
President And Fellows Of Harvard College |
Cellular reprogramming to reverse aging and promote organ and tissue regeneration
|
JP2022501060A
(ja)
|
2018-09-28 |
2022-01-06 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
遺伝子の発現のための変異体リバーステトラサイクリントランスアクチベーター
|
US20220033824A1
(en)
|
2018-11-29 |
2022-02-03 |
University Of Massachusetts |
Modulation of sptlc1 via recombinant adeno-associated vectors
|
CN113557035A
(zh)
|
2019-01-12 |
2021-10-26 |
卫理公会医院 |
自组装肽纳米颗粒和其用途
|
EP3921029A4
(fr)
|
2019-02-07 |
2022-12-07 |
Baylor College of Medicine |
Cellules souches squelettiques périostales dans une réparation osseuse
|
US20220054655A1
(en)
|
2019-02-22 |
2022-02-24 |
University Of Massachusetts |
Oxr1 gene therapy
|
US11717506B2
(en)
|
2019-05-07 |
2023-08-08 |
The Johns Hopkins University |
Neuroprotective compounds for amyotrophic lateral sclerosis
|
CN114555814A
(zh)
|
2019-09-13 |
2022-05-27 |
罗特格斯新泽西州立大学 |
Aav相容的层粘连蛋白-连接子聚合蛋白
|
US20220380735A1
(en)
|
2019-10-10 |
2022-12-01 |
Oncorus, Inc. |
Dual viruses and dual oncolytic viruses and methods of treatment
|
EP4045665A4
(fr)
|
2019-10-15 |
2023-11-15 |
University of Massachusetts |
Trans-épissage d'arn amélioré par éditeur d'arn
|
WO2021113644A1
(fr)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinaisons comprenant un activateur de lymphocytes t cd8+, un inhibiteur de point de contrôle immunitaire et une radiothérapie en vue d'obtenir des effets ciblés et abscopal pour le traitement du cancer
|
KR20220144377A
(ko)
|
2020-01-30 |
2022-10-26 |
우모자 바이오파마 인코포레이티드 |
이중특이적 형질도입 촉진제
|
MX2022012279A
(es)
|
2020-03-31 |
2023-02-23 |
Univ Massachusetts |
Variantes de capsides de aav y usos de los mismos.
|
US11965162B2
(en)
|
2020-04-16 |
2024-04-23 |
The Johns Hopkins University |
MicroRNA and inhibitors thereof and methods of treatment
|
AU2021321944A1
(en)
|
2020-08-07 |
2023-04-06 |
Access To Advanced Health Institute |
Purified saponins and chromatographic process for purification of same
|
EP4255457A1
(fr)
|
2020-12-03 |
2023-10-11 |
University of Massachusetts |
Développement de nouvelles thérapies géniques pour la fibrodysplasie ossifiante progressive
|
KR20220082558A
(ko)
|
2020-12-10 |
2022-06-17 |
재단법인 의약바이오컨버젼스연구단 |
면역 증진 활성이 있는 신규 crs 단편 펩타이드 및 이의 용도
|
MX2023008831A
(es)
|
2021-01-27 |
2023-10-19 |
Umoja Biopharma Inc |
Lentivirus para generar células que expresan receptores de antígeno quimérico anti-cd19.
|
US20240200078A1
(en)
|
2021-11-18 |
2024-06-20 |
Cornell University |
Microrna-dependent mrna switches for tissue-specific mrna-based therapies
|
GB2614309A
(en)
|
2021-12-24 |
2023-07-05 |
Stratosvir Ltd |
Improved vaccinia virus vectors
|
WO2023144393A1
(fr)
|
2022-01-28 |
2023-08-03 |
Fundació Centre De Regulació Genòmica |
Cytokines thérapeutiques et méthodes
|
WO2023144792A1
(fr)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
Conjugués poly(alkyloxazoline)-lipide et particules lipidiques les contenant
|
WO2023144798A1
(fr)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
Lipides cationiques ionisables pour nanoparticules lipidiques
|
WO2023196851A1
(fr)
|
2022-04-06 |
2023-10-12 |
President And Fellows Of Harvard College |
Inversion du vieillissement du système nerveux central
|
WO2023215481A1
(fr)
|
2022-05-05 |
2023-11-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Thérapie par arn interférant pour la cardiomyopathie pln-r14del
|
WO2023225569A1
(fr)
|
2022-05-17 |
2023-11-23 |
Umoja Biopharma, Inc. |
Fabrication de particules virales
|
WO2024097992A2
(fr)
|
2022-11-04 |
2024-05-10 |
Umoja Biopharma, Inc. |
Particules présentant des fusions de molécules d'adhésion
|